李氏大药厂(00950.HK)联营眼科产品招募首名临床试验对象
李氏大药厂(00950.HK)公布,联营公司兆科眼科於中国成功招募首名病人在II期临床试验中使用滴眼液ZKY001。该产品通过抗炎作用及刺激上皮细胞迁移,治疗角膜上皮缺损,为中国目前唯一的临床阶段角膜上皮缺损候选药物。
此临床试验的设计为招募合共105名对象,於完成该项I期临床试验後,兆科眼科已就启动II期临床试验谘询国家药监局药审中心,沟通後药审中心认为目前可得数据充分表明ZKY001的安全特性,可开展後续的试验。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.